Q2
ABVC — Q2 2026 Financial Report Analysis
ABVC BioPharma's Q2 2026 net loss fell 67% to $0.74 million as a year-ago stock payout to advisors did not repeat, but it ended June with just $31,944 in cash, a $5.28 million working-capital deficit and a going-concern warning.